Osoresnontrine
- Generic Name
- Osoresnontrine
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N5O2
- CAS Number
- 1189767-28-9
- Unique Ingredient Identifier
- O9OC34WOAY
- Background
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02248259
- Locations
- 🇰🇷
1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02240693
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇫🇷HOP Jean Bernard, Géria, Poitiers, Poitiers, France
🇩🇪Praxis Dr. med. Volker Schumann, Berlin, Germany
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02222168
- Locations
- 🇩🇪
1289.22.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01892384
- Locations
- 🇺🇸
1289.18.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01611311
- Locations
- 🇩🇪
1289.17.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT01505894
- Locations
- 🇩🇪
1289.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01493570
- Locations
- 🇧🇪
1289.3.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
Safety Tolerability and Pharmacokinetic of BI 409306
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT01343706
- Locations
- 🇩🇪
1289.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.